Bill · H.R. 8260· House(119-HR-8260)
Cardiovascular Disease Early Detection and Prevention Act of 2026
- Introduced
- 4/14/2026
- Last activity
- 4/14/2026 — Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
- Sponsored by
- Sheila Cherfilus-McCormick
- Cosponsors
- None
- Introduced
- In Committee
What this bill would do
The Cardiovascular Disease Early Detection and Prevention Act of 2026 seeks to amend existing health laws to mandate coverage for specific cardiovascular tests. It specifically targets testing for lipoprotein(a) and apolipoprotein B levels. These tests must be covered without cost sharing for individuals with certain risk factors, such as a family history of cardiovascular disease or a diagnosis of diabetes or obesity. The mandate applies to group health plans, individual health insurance, Medicare, and Medicaid. This ensures that specific cardiovascular risk assessments are available to those at risk without out-of-pocket expenses.
Yes· 3 of 6
Would households on low incomes be better off under this?+5
The bill enhances Medicaid coverage to ensure low-income individuals can access cardiovascular risk tests without out-of-pocket costs.
Does this make health care easier to get in general?+5
The bill increases access to essential cardiovascular screenings by removing financial barriers for high-risk populations.
Would people over 65 be better off under this?+4
The bill improves Medicare coverage for specific life-saving cardiovascular screenings for seniors at risk.
The opposite
No question was scored the opposite.
Who it would affect, and how
Potential Positive Impacts for People
-
Mandatory Coverage of Essential Tests: The bill requires coverage for lipoprotein(a) and apolipoprotein B level testing for people with specific risk factors, including a family history of premature cardiovascular disease, personal history of myocardial infarction, stroke, or elevated LDL cholesterol, or a diagnosis of diabetes mellitus or obesity (Section 3(a), 3(b), and 3(c)).
-
Elimination of Out-of-Pocket Costs: The legislation ensures these specific cardiovascular tests are provided without cost sharing under group health plans, individual health insurance, Medicare, and Medicaid (Section 3).
-
Improved Risk Management: The bill's findings note that elevated ApoB levels predict cardiovascular risk better than LDL cholesterol alone and that many heart attack survivors die without effective risk management (Section 2). By requiring these tests, the bill aims to address these risks (Section 3).
Potential Negative Impacts for People
- No specific negative impacts or burdens are explicitly stated in the provided text.
Groups and Interests Ranking
Every group the model scored this bill for, from -10 to +10. Hover a score for the reason it gave.
- Demographic And Interest Groups
- Good For Low Income Households+5Good For Retirees+4Good For Seniors+4
- Healthcare
- Improves Healthcare Access+5Increases Medicaid Funding+3Increases Medicare Funding+3
- 4/14/2026
- Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
- Introduced in House